Home Newsletters Hematopoiesis News Impact of Prior JAK-Inhibitor Therapy with Ruxolitinib on Outcome after Allogeneic Hematopoietic...

Impact of Prior JAK-Inhibitor Therapy with Ruxolitinib on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Study of the CMWP of EBMT

By
Justin.choi
-
0
The authors studied the impact of pretreatment with JAK1/2 inhibitor ruxolitinib on patient outcome after allogeneic hematopoietic stem cell transplantation.
[Leukemia]

Sorry, but the selected Zotpress account can't be found.

Full Article

RELATED ARTICLES

Exit mobile version